Humacyte, Inc. (HUMA): Results of Operations and Financial Condition
Humacyte, Inc. (HUMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622949d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update – Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic
How this was made
The 30-second read
Why it matters
Key new disclosures are the V012 Phase 3 interim efficacy/safety results in women, the planned 2H 2026 supplemental BLA filing for ATEV, and FDA IND acceptance for the CTEV CABG first-in-human study with Phase 2a planned for Q3 2026.
Market read
Traders can update probabilities around Humacyte’s regulatory path for dialysis access (sBLA timing) and near-term clinical execution for coronary indications (Phase 2a start).
What to watch
Commercial execution for Symvess is still early, with Q2 sales only $0.4M, so valuation may hinge more on regulatory outcomes than current revenue traction.
Background
This SEC 8-K (Item 2.02) accompanies Humacyte’s Q2 2026 financial results and pipeline/business update, including dialysis access and coronary vessel programs.
Ticker impact
Humacyte reports V012 Phase 3 interim results in female dialysis patients and says it will file a supplemental BLA in 2H 2026.
Bias to upside on any market reaction, with follow-through risk tied to FDA review timing and durability of Phase 3 data.
This 8-K discloses new, decision-relevant clinical and regulatory milestones (sBLA timing, FDA IND acceptance for CTEV, and Phase 2a start plan) plus a small Symvess sales datapoint.
Market effects
Could strengthen sentiment around vascular access and bioengineered tissue platforms, potentially improving risk appetite for similar late-stage biotech programs.
Limited direct regional spillover; primary impact is on US-listed biotech sentiment.
Moderate, as dialysis access and CABG conduit innovation are globally relevant but the disclosed milestones are US-regulatory driven.
Counterpoint
Interim analysis of the first 80 patients may not fully de-risk the full Phase 3 readout, and FDA acceptance does not guarantee approval or timeline.
Key entities
- companyHumacyte, Inc.
Commercial-stage biotech developing bioengineered human tissues; subject of the 8-K and pipeline update.
- clinical_programV012 Phase 3 (ATEV)
Dialysis access Phase 3 interim analysis in female patients; ATEV outperformed AV fistula on catheter-free days and showed fewer infections per 100 patient years.
- regulatorFDA
Accepted IND for CTEV first-in-human study and is the target agency for the planned supplemental BLA filing.
- clinical_programCTEV (CABG)
Coronary tissue engineered vessel program; IND accepted and Phase 2a planned for CABG during Q3 2026.
- productSymvess
Humacyte’s commercial product; Q2 2026 sales disclosed as $0.4M vs $0.1M in 2025.
